Search
Displaying 351–360 of 661 for “retinal diseases”
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
Research NewsThe goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
VisionWalk Home Page
-
AGTC Announces Development of Stargardt Disease Gene Therapy
Research NewsDual-vector delivery system designed to deliver the large ABCA4 gene
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy
Research NewsProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy known as QR-110
-
First Patient Treated in XLRP Gene Therapy Clinical Trial
Research NewsThe Nightstar gene therapy involves injection of healthy copies of RPGR underneath the retina.
-
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Taking Their Story of Vision Loss on the Road
Beacon StoriesRollie and Sandie Purvis, parents of two sons with choroideremia, describe their sons’ film project, “Driving Blind.”
-
Belite Bio to Seek FDA Approval for its Stargardt Disease Drug
Research NewsTinlarebant slowed disease progression by 36 percent in the Dragon Phase 3 clinical trial.
-
Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial
Research NewsThe emerging therapy improved vision for some participants in an earlier clinical trial.
